Castration‐resistant prostate cancer diagnosed during leuprorelin treatment for spinal and bulbar muscular atrophy. Issue 4 (10th April 2022)

• Record Type: Journal Article
• Authors: Yanase, Atsuhi; Sugihara, Toru; Akimoto, Takahiro; Yokoyama, Hirotaka; Kamei, Jun; Fujisaki, Akira; Ando, Satoshi; Naoi, Tameto; Morita, Mitsuya; Fujimura, Tetsuya
• Is Part Of: IJU case reports. Volume 5:Issue 4(2022)
• Page Start: 251
• Page End: 254
• Publication Date: 2022-04-10
• Subjects: androgen receptor -- leuprorelin acetate -- motor neuron disease -- prostate cancer -- spinal and bulbar muscular atrophy; Urology -- Periodicals; Genitourinary organs -- Periodicals; Electronic journals; Periodicals; 616.6
• DOI: 10.1002/iju5.12447
• Languages: English
• ISSNs: 2577-171X

Abstract

Abstract : Introduction: We report a prostate cancer case diagnosed during leuprorelin treatment for spinal and bulbar muscular atrophy which is a X‐linked recessive, lower motor neuron disease. Case presentation: A 64‐year‐old man who had received leuprorelin treatment over 3 years for his spinal and bulbar muscular atrophy presented with an enlarged prostate accompanied by abdominal pain and constipation. An abnormally high serum prostate‐specific antigen of 17.7 ng/mL and a low (castration level) serum testosterone level of 0.23 ng/mL were measured. Prostate needle biopsy revealed adenocarcinoma of the prostate. Orchiectomy, darolutamide, and radiation therapy for the prostate were initiated, resulting in a favorable response which was maintained at 12 months of treatment. Conclusion: Prostate cancer can occur even when leuprorelin is used for spinal and bulbar muscular atrophy; therefore, checking serum prostate‐specific antigen to screen for prostate cancer before leuprorelin administration should be considered.